Literature DB >> 19330009

Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans.

Hiroshi Watanabe1, Nagesh Chopra, Derek Laver, Hyun Seok Hwang, Sean S Davies, Daniel E Roach, Henry J Duff, Dan M Roden, Arthur A M Wilde, Björn C Knollmann.   

Abstract

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal inherited arrhythmia syndrome in which drug therapy is often ineffective. We discovered that flecainide prevents arrhythmias in a mouse model of CPVT by inhibiting cardiac ryanodine receptor-mediated Ca(2+) release and thereby directly targeting the underlying molecular defect. Flecainide completely prevented CPVT in two human subjects who had remained highly symptomatic on conventional drug therapy, indicating that this currently available drug is a promising mechanism-based therapy for CPVT.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19330009      PMCID： PMC2904954          DOI： 10.1038/nm.1942

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  17 in total

1.  Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia.

Authors:  Uwais Mohamed; Michael H Gollob; Robert M Gow; Andrew D Krahn
Journal:  Heart Rhythm       Date:  2006-08-25       Impact factor: 6.343

2.  Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia.

Authors:  Björn C Knollmann; Nagesh Chopra; Thinn Hlaing; Brandy Akin; Tao Yang; Kristen Ettensohn; Barbara E C Knollmann; Kenneth D Horton; Neil J Weissman; Izabela Holinstat; Wei Zhang; Dan M Roden; Larry R Jones; Clara Franzini-Armstrong; Karl Pfeifer
Journal:  J Clin Invest       Date:  2006-08-24       Impact factor: 14.808

3.  A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel.

Authors:  H Lahat; E Pras; T Olender; N Avidan; E Ben-Asher; O Man; E Levy-Nissenbaum; A Khoury; A Lorber; B Goldman; D Lancet; M Eldar
Journal:  Am J Hum Genet       Date:  2001-10-25       Impact factor: 11.025

4.  Reducing ryanodine receptor open probability as a means to abolish spontaneous Ca2+ release and increase Ca2+ transient amplitude in adult ventricular myocytes.

Authors:  L A Venetucci; A W Trafford; M E Díaz; S C O'Neill; D A Eisner
Journal:  Circ Res       Date:  2006-04-13       Impact factor: 17.367

5.  The interaction of local anesthetics with the ryanodine receptor of the sarcoplasmic reticulum.

Authors:  V Shoshan-Barmatz; S Zchut
Journal:  J Membr Biol       Date:  1993-04       Impact factor: 1.843

6.  Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia.

Authors:  Arthur A M Wilde; Zahurul A Bhuiyan; Lia Crotti; Mario Facchini; Gaetano M De Ferrari; Thomas Paul; Chiara Ferrandi; Dave R Koolbergen; Attilio Odero; Peter J Schwartz
Journal:  N Engl J Med       Date:  2008-05-08       Impact factor: 91.245

7.  Sudden death in a young man with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation.

Authors:  Stephen Pizzale; Michael H Gollob; Robert Gow; David H Birnie
Journal:  J Cardiovasc Electrophysiol       Date:  2008-06-12

8.  Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients.

Authors:  A Leenhardt; V Lucet; I Denjoy; F Grau; D D Ngoc; P Coumel
Journal:  Circulation       Date:  1995-03-01       Impact factor: 29.690

9.  Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia.

Authors:  Marina Raffaele di Barletta; Serge Viatchenko-Karpinski; Alessandra Nori; Mirella Memmi; Dmitry Terentyev; Federica Turcato; Giorgia Valle; Nicoletta Rizzi; Carlo Napolitano; Sandor Gyorke; Pompeo Volpe; Silvia G Priori
Journal:  Circulation       Date:  2006-08-14       Impact factor: 29.690

10.  Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia.

Authors:  Marina Cerrone; Sami F Noujaim; Elena G Tolkacheva; Arkadzi Talkachou; Ryan O'Connell; Omer Berenfeld; Justus Anumonwo; Sandeep V Pandit; Karen Vikstrom; Carlo Napolitano; Silvia G Priori; José Jalife
Journal:  Circ Res       Date:  2007-09-13       Impact factor: 17.367
View more
  186 in total

1.  Pharmacology and Toxicology of Nav1.5-Class 1 anti-arrhythmic drugs.

Authors:  Dan M Roden
Journal:  Card Electrophysiol Clin       Date:  2014-12-01

2.  Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.

Authors:  Hyun Seok Hwang; Can Hasdemir; Derek Laver; Divya Mehra; Kutsal Turhan; Michela Faggioni; Huiyong Yin; Björn C Knollmann
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-01-26

Review 3.  Inherited calcium channelopathies in the pathophysiology of arrhythmias.

Authors:  Luigi Venetucci; Marco Denegri; Carlo Napolitano; Silvia G Priori
Journal:  Nat Rev Cardiol       Date:  2012-06-26       Impact factor: 32.419

4.  Calcium polymorphic ventricular tachycardia: a new name for CPVT?

Authors:  Fabien Brette
Journal:  Cardiovasc Res       Date:  2010-05-13       Impact factor: 10.787

5.  Gene therapy for inherited arrhythmias.

Authors:  Vassilios J Bezzerides; Maksymilian Prondzynski; Lucie Carrier; William T Pu
Journal:  Cardiovasc Res       Date:  2020-07-15       Impact factor: 10.787

Review 6.  The renal plumbing system: aquaporin water channels.

Authors:  L N Nejsum
Journal:  Cell Mol Life Sci       Date:  2005-08       Impact factor: 9.261

Review 7.  Genetics of sudden cardiac death caused by ventricular arrhythmias.

Authors:  Roos F Marsman; Hanno L Tan; Connie R Bezzina
Journal:  Nat Rev Cardiol       Date:  2013-12-10       Impact factor: 32.419

8.  A novel cardiac ryanodine receptor gene (RyR2) mutation in an athlete with aborted sudden cardiac death: a case of adult-onset catecholaminergic polymorphic ventricular tachycardia.

Authors:  Junko Arakawa; Akira Hamabe; Takeshi Aiba; Tomoo Nagai; Mikoto Yoshida; Takumi Touya; Norio Ishigami; Hideki Hisadome; Shuichi Katsushika; Hirotsugu Tabata; Yoshihiro Miyamoto; Wataru Shimizu
Journal:  Heart Vessels       Date:  2014-08-05       Impact factor: 2.037

9.  Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass.

Authors:  Fredrick A Hilliard; Derek S Steele; Derek Laver; Zhaokang Yang; Sylvain J Le Marchand; Nagesh Chopra; David W Piston; Sabine Huke; Björn C Knollmann
Journal:  J Mol Cell Cardiol       Date:  2009-10-14       Impact factor: 5.000

Review 10.  Atrial Ca2+ signaling in atrial fibrillation as an antiarrhythmic drug target.

Authors:  Dobromir Dobrev
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-09-26       Impact factor: 3.000
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.